Grail's Galleri Multi-Cancer Blood Test Faces Coverage Hurdle
Grail's Galleri test screens for 50 cancers from a single blood draw, but FDA approval and insurance coverage remain uncertain after a key study fell short.
A blood test capable of screening for 50 types of cancer at once is drawing significant attention in the health-care industry, but its path to widespread coverage by Medicare and private insurers runs directly through the U.S. Food and Drug Administration — and that approval is not yet secured.
Grail's Galleri test works by analyzing a blood sample for biological signals associated with dozens of cancer types, offering the prospect of earlier detection across malignancies that currently lack routine screening tools. The technology represents a new frontier in so-called multi-cancer early detection, a field that has attracted billions in investment and considerable patient hope.
Read more Canada Urges UK Partnership Amid EU Associate Membership Talk →
However, a major clinical study examining the test failed to demonstrate that Galleri could reliably detect cancers at later stages of disease progression — a finding that has complicated the regulatory picture. The result underscores the gap that can exist between a test's conceptual promise and its proven clinical performance under rigorous scientific scrutiny.
Without FDA clearance or approval, Medicare coverage remains out of reach under current federal rules governing reimbursement for diagnostic tests. Private insurers are similarly unlikely to add Galleri to standard benefit packages without a formal regulatory green light, meaning most patients who want the test today would have to pay out of pocket at a cost that puts it beyond reach for many Americans.
The outcome of Grail's regulatory pursuit will likely set a precedent for how the broader multi-cancer detection industry is evaluated, covered, and integrated into routine preventive care in the United States. Continue reading at MarketWatch.com
